Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer Read More

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib) Read More

Astellas Helps Veterans Compete in 2019 Warrior Games

Astellas Helps Veterans Compete in 2019 Warrior Games Read More

1

2

3

4

News

Latest

News / Media

Jul 17, 2019

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

News / Media

Jul 17, 2019

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

News / Media

Jul 10, 2019

Launch of Smyraf^® Tablets - Provides a new therapeutic option for rheumatoid arthritis in patients who have an inadequate response to conventional therapies -

News / Corporate

Jul 16, 2019

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

News / Corporate

Jul 10, 2019

Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales

News / Corporate

Jun 03, 2019

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer